基于第三类活性药物分类的抗逆转录病毒治疗方案CD4/CD8比值结局:魁北克HIV队列研究结果
该研究利用魁北克HIV队列截至2017年8月31日的数据,纳入3907例接受含2种核苷类逆转录酶抑制剂加第三类活性药物(非核苷类逆转录酶抑制剂、蛋白酶抑制剂或整合酶链转移抑制剂)至少16周的患者,采用边际结构Cox模型分析。结果显示,与整合酶链转移抑制剂方案相比,非核苷类逆转录酶抑制剂方案和蛋白酶抑制剂方案达到CD4/CD8比值≥1的风险比分别为0.56和0.41。作者认为,基于整合酶链转移抑制剂的抗逆转录病毒治疗似乎与更高的CD4/CD8比值相关。
要点
- 纳入3907例,非核苷类、蛋白酶抑制剂、整合酶链转移抑制剂组分别占24.9%、51.1%、24.0%。
- 以整合酶链转移抑制剂为参照,非核苷类组CD4/CD8比值≥1的加权风险比为0.56(95%CI 0.48-0.65)。
- 以整合酶链转移抑制剂为参照,蛋白酶抑制剂组CD4/CD8比值≥1的加权风险比为0.41(95%CI 0.35-0.47)。
核心结论
- 对于接受HIV治疗的人群,基于整合酶链转移抑制剂的抗逆转录病毒治疗似乎与更高的CD4/CD8比值相关,高于基于非核苷类逆转录酶抑制剂和蛋白酶抑制剂的方案。
研究设计与样本
- 研究使用魁北克HIV队列截至2017年8月31日收集的数据。
- 纳入队列中所有接受首个或后续抗逆转录病毒治疗方案、由2种核苷类逆转录酶抑制剂加第三类活性药物(非核苷类逆转录酶抑制剂、蛋白酶抑制剂或整合酶链转移抑制剂)组成且持续至少16周的患者。
- 采用边际结构Cox模型估计不同治疗类别对CD4/CD8比值结局的影响。
主要发现
- 3907例符合条件患者中,972例(24.9%)暴露于第三类活性药物为非核苷类逆转录酶抑制剂的方案,1996例(51.1%)暴露于蛋白酶抑制剂方案,939例(24.0%)暴露于整合酶链转移抑制剂方案。
- 总随访时间为13640.24人年。
- 与暴露于整合酶链转移抑制剂+2种核苷类逆转录酶抑制剂的患者相比,暴露于非核苷类逆转录酶抑制剂+2种核苷类逆转录酶抑制剂的患者CD4/CD8比值≥1的加权风险比为0.56(95%CI 0.48-0.65)。
- 与暴露于整合酶链转移抑制剂+2种核苷类逆转录酶抑制剂的患者相比,暴露于蛋白酶抑制剂+2种核苷类逆转录酶抑制剂的患者CD4/CD8比值≥1的加权风险比为0.41(95%CI 0.35-0.47)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The impact of different therapeutic classes of drugs in antiretroviral therapy (ART) regimens on the CD4/CD8 ratio is not well documented in people treated for HIV. The objective of this study was to analyze the long-term effect of exposure to integrase strand transfer inhibitor (INSTI) on CD4/CD8 ratio compared with nonnucleoside reverse transcriptase inhibitor (NNRTI) or protease inhibitor (PI) among ART-treated persons with HIV (PWH). METHODS: Data from the Quebec HIV Cohort collected from 31 August 2017 were used. Our analysis included all patients in the cohort who received a first or subsequent ART regimen composed of 2 nucleoside reverse transcriptase inhibitors (NRTIs) and a third active drug of a different class (NNRTI, PI, or INSTI) for at least 16 weeks. Marginal structural Cox models were constructed to estimate the effect of different therapeutic classes on the CD4/CD8 ratio outcome. RESULTS: Among the 3907 eligible patients, 972 (24.9%), 1996 (51.1%), and 939 (24.0%) were exposed to an ART regimen whose third active agent was an NNRTI, PI, or INSTI, respectively. The total follow-up time was 13 640.24 person-years. The weighted hazard ratio for the association between the third active class and CD4/CD8 ratio ≥1 was .56 (95% confidence interval [CI]: .48-.65) for patients exposed to NNRTI + 2 NRTIs and .41 (95% CI: .35-.47) for those exposed to PI + 2 NRTIs, compared with those exposed INSTI + 2 NRTIs. CONCLUSIONS: For people treated for HIV, INSTI-based ART appears to be associated with a higher CD4/CD8 ratio than NNRTI and PI-based ART.
引用
- Sangaré MN, Baril JG, de Pokomandy A, et al. CD4/CD8 Ratio Outcome According to the Class of the Third Active Drug in Antiretroviral Therapy Regimens: Results From the Quebec Human Immunodeficiency Virus Cohort Study. Clin Infect Dis. 2023. PMID: 36722329. doi:10.1093/cid/ciad056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。